Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Multi Cap Fund median (29 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 07 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 500 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | Quant Multi Cap Fund |
|---|---|
| 07 Jan 2013 | ₹100.00 |
| 25 Feb 2014 | ₹95.19 |
| 16 Apr 2015 | ₹158.78 |
| 03 Jun 2016 | ₹152.78 |
| 23 Jul 2017 | ₹171.48 |
| 10 Sep 2018 | ₹190.14 |
| 30 Oct 2019 | ₹200.15 |
| 17 Dec 2020 | ₹266.92 |
| 04 Feb 2022 | ₹452.56 |
| 26 Mar 2023 | ₹432.15 |
| 13 May 2024 | ₹703.23 |
| 02 Jul 2025 | ₹702.81 |
| 20 Aug 2026 | ₹734.85 |
| Metric | quant · Direct · IDCW NAV ₹84.12 Very High risk ★★☆☆☆ | Category median Multi Cap Fund · 29 funds |
|---|---|---|
| +7.66% | +6.55% | |
| +11.79% | +13.71% | |
| +13.70% | +12.07% | |
| +16.41% | +9.16% | |
| +15.78% | +14.55% | |
| +10.78% | — | |
| +18.12% | +17.33% | |
| +18.53% | +14.39% | |
| +17.64% | +9.74% | |
| Risk | ||
| 17.06% | 15.40% | |
| 0.31 | 0.41 | |
| 0.41 | 0.54 | |
| -36.30% | -21.00% | |
| Nifty 500 | — | |
| -0.76% | +1.30% | |
| 1.09 | 1.03 | |
| 104.5% | 104.7% | |
| 112.2% | 99.6% | |
| 0.99% | 0.93% | |
| ₹7,499Cr | ₹4,007Cr | |
| 1.00% | — | |
| None | — | |
| ₹2.03K | — | |
| ₹5.00K | — | |
| 0% | 53% | |
| Varun Pattani · 1.5y | — | |
| 07 Jan 2013 | — | |
| 47 | — | |
| 42.2% | — | |
| 5.8% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.